Suven Life Sciences' Q4 FY 2025-26 Quarterly Results

Result Summary

• Suven Life Sciences Ltd reported a 48.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 208.6%.
• Its expenses for the quarter were down by 49.9% QoQ and up 15.5% YoY.
• The net profit decreased 55.3% QoQ and increased 3.8% YoY.
• The earnings per share (EPS) of Suven Life Sciences Ltd declined at 2.02 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Suven Life Sciences Ltd is a biopharmaceutical company engaged in the development of novel therapeutics for the treatment of central nervous system (CNS) disorders. The company's main focus is on discovering and developing new chemical entities (NCEs) for cognitive disorders, depression, and other CNS ailments. Suven Life Sciences operates within the highly competitive pharmaceutical industry, which is characterized by significant research and development activities. Recent major developments for the company are not available from the provided data.

Revenue

In the fourth quarter of fiscal year 2026 (Q4FY26), Suven Life Sciences Ltd reported total income of ₹8.30 crores, which represents a significant increase compared to ₹5.58 crores in the third quarter of fiscal year 2026 (Q3FY26) and ₹2.69 crores in the fourth quarter of fiscal year 2025 (Q4FY25). This translates to a quarter-over-quarter (QoQ) growth of 48.7% and a year-over-year (YoY) growth of 208.6%. The substantial YoY growth in total income highlights an upward trend in revenue generation for the company during this period.

Profitability

The profitability metrics for Suven Life Sciences in Q4FY26 indicate a loss, with a reported profit before tax and profit after tax both at -₹45.60 crores. This is a reduction in losses compared to the -₹101.92 crores recorded in Q3FY26 and slightly more negative than the -₹43.94 crores reported in Q4FY25. The company experienced a 55.3% QoQ reduction in losses, alongside a 3.8% increase in losses YoY. Earnings per share (EPS) for Q4FY26 stood at -₹2.02, showing an improvement from -₹4.55 in Q3FY26, but unchanged compared to Q4FY25.

Operating Metrics

During Q4FY26, the company's total expenses were ₹53.89 crores, marking a significant decrease from ₹107.51 crores in Q3FY26, yet an increase from ₹46.64 crores in Q4FY25. The expenses saw a 49.9% QoQ decline and a 15.5% YoY increase. The zero tax expense across all quarters analyzed points to a consistent tax strategy or operational losses not generating tax liabilities. Notably, the consistent EPS of -₹2.02 in both Q4FY26 and Q4FY25, despite decreased losses, highlights a stable share structure or consistent earnings in relation to shares outstanding.